BOARD OF DIRECTORS
The Board of directors of i-Lumen Scientific has been carefully chosen to combine highly-experienced individuals with track records of success in leading, managing, and growing medical device businesses. The Board, with its strong business expertise, gives strong guidance, successfully aiding the management team in its goal of building i-Lumen into the world leader in vision restoration.
Blair P. Mowery, Chairman
Mr. Mowery is Chairman of the Board. Prior to joining the Company, Mr. Mowery was President and CEO for Acuity Medical, an ophthalmic medical device company. Prior to that he was with THE M&A GROUP where he was the VP for Medical Technology and an Operating Partner. He was responsible for assisting small to midsize medical companies in the areas of business development and merger strategies. Prior to that, he was COO of CathEffects, Inc., a medical device company located in California, which developed catheter products for mapping and ablation of arrhythmias. He also served as Chief Executive Officer of Medical CV, Inc., a global cardiovascular company, which he took public in 2001. Prior to that, Mr. Mowery was President and Chief Operating Officer of GalaGen, Inc., a biopharmaceutical company, and President of Procor Technologies, a joint venture with Abbott Ross Laboratories. Mr. Mowery has extensive medical device experience in global marketing and sales, technology licensing and enterprise building. Mr. Mowery graduated from North Dakota State University with a BA in Marketing and Business Management.
Robert Warner, Director
Mr. Warner is the former President of Alcon Laboratories, a global leader in ophthalmic medical devices, consumer products, and pharmaceuticals. Mr Warner has extensive international ophthalmic sales and marketing experience, as well as general management, and mergers and acquisitions expertise. He was responsible for Alcon's medical device, pharmaceutical, and consumer products for the US and Canada, and prior to that for Latin America and Canada. Prior to his lengthy tenure at Alcon, he was with Boehringer Ingelheim Pharmaceuticals, and Sun Chemical Corporation. Mr. Warner received his BA in Chemistry from Pace University, and his MBA with a concentration in Finance, from Rutgers, The State University of New Jersey.
Robert D. Ahmann, Director
Mr. Ahmann is currently President of Tautex, a small firm he founded in 2007 that specializes in the commercialization of medical and related technology, and has worked closely with the technology commercialization branch of Mayo Clinic. Mr. Ahmann was a co-founder in 1994 of Pemstar a $900 Million annual sales company located in Rochester, Minnesota, which was sold to Benchmark Electronics Company in 2006. Mr. Ahmann served as Executive Vice President of Engineering, and he served as a member of the company’s Board of Directors. As EVP of Engineering, he was responsible for 400 engineers worldwide, where much of their work focused on developing medical products. This included the development and manufacturing of medical devices for companies like Medtronic, Johnson & Johnson, Guidant, Baxter, Beckton Dickinson, Mayo Clinic, Given Imaging, and others. Mr. Ahmann holds a B.S.E.E. from North Dakota State University and an M.S.E.E. from the University of Minnesota.
Gregory D. Cash, Director
Mr. Cash is President & CEO, of Argent International, a lifesciences firm he founded. Prior to this, he was President, CEO and a director for CardioBility, Inc. And, before that he was President & CEO of BioSig Technologies, Inc. He has over thirty years of business experience and has been chief executive officer of several companies, both public and privately held, and has run global business units of larger companies. Previous positions include President and Chief Executive Officer of NeuroTherm, Inc., President and Chief Executive Officer, as well as a director of HeartSine Technologies, Inc., President, Vascular Therapy and New Businesses for Sorin Group based in Milan, Italy, President and Chief Executive Officer and a director of Vasomedical, Inc. a NASDAQ traded public company, and spent five years with Boston Scientific Corporation, ultimately as Vice President, Cardiology Sales and Marketing, Europe. He began his career at Medtronic, Inc., serving fourteen years in increasingly senior sales and marketing positions.
Chris Pulling, Director
Mr. Pulling is CEO of the Ophthalmic Clinical-stage Medical Device start-up MicroOptx, and has over 30 years experience in the medical device and clinical and regulatory fields. MicroOptx has raised approximately $24.5M in capital, including $17M in Q2-2019, and initiated a US pivotal clinical study in Q3-2019. Chris was previously CEO of The Integra Group, a contract medical research organization he founded in 2002 and later sold to the world's largest contract organization in the medical device sector. At that time, Integra was assisting over 400 pre-market medical device companies in all aspects of research and development. Chris was personally involved in over 30 original PMA approvals and even more 510(k) clearances. Prior to Integra, he built and ran Medtronic’s Cardiac Rhythm Management's Biostatistics function. Chris has an MS in Biostatistics from the University of Minnesota and was recently just the fourth recipient of the U of MN’s School of Public Health Alumni Innovator Award.
Michael Glover, Director
Mr. Glover has 37 years of experience as an AV rated lawyer practicing in areas including corporate litigation, securities, corporate governance, insurance, officer and director liability and patent and trademark litigation. Mr. Glover has sat on multiple Boards of corporations and has acted as general counsel on several others, including his role as counsel to i-Lumen for the previous two and a half years. Mr. Glover's extensive legal experience and historical knowledge of I-Lumen and its technology, provides a valuable resource for the I-Lumen Board in its decision making and strategic planning for the future of the company.
The management of i-Lumen Scientific is comprised of a hand-selected group of highly qualified and experienced individuals tasked with building the Company into the world-wide leader in the treatment of dry AMD. Each member of the management team has an impressive track record of medical device and business successes, and was chosen for their unique contribution to the business, marketing, and expansion needs of
i-Lumen Scientific's products and therapies, as well as the successful implementation of its business strategy and business model. This is a group of individuals with considerable experience in taking companies from a startup position, to successful market entry, to impressive expansion.
John VeLure, (President & CEO)
Mr. VeLure has extensive experience, and a track record of consistent success, as a senior executive and veteran of the medical device and digital healthcare industries. Most recently, Mr. VeLure was SVP, Corporate Development at Medibio Limited, a publicly traded, digital health company that provides objective assessment tools for mental health disorders. Mr. VeLure founded Neurotech NA, Inc., a neurostimulation company that commercialized devices to accelerate non-surgical and post-operative rehabilitation. Serving as its CEO, he completed the sale of Neurotech NA to Theragen in 2015. Mr. VeLure served as the Senior Director of Marketing and Business Development for Compex Technologies, Inc. managing both a direct and distributor based sales organization, and securing OEM supplier and product licensing agreements for both the US and international markets. Prior to this, he was Director of Sales and Marketing for American MedTech, Inc., a Urology company that distributed FDA Cleared, devices for Erectile Disfunction and Incontinence. Mr. VeLure has a BA double major in Economics and Business Administration from Augustana College in Sioux Falls, SD.
Marshall T. Masko, (Co-Founder & COO)
Mr. Masko is Co-Founder of I-Lumen Scientific, and serves as the Company's COO. He has extensive ophthalmic medical device leadership experience, as well as marketing expertise in the fields of direct response marketing, CPG marketing, international marketing, medical device marketing, and retail sales, with a track record of success to match. Mr. Masko was previously President of Compex Technologies, Inc. (Worldwide Consumer Products), headquartered in Switzerland, a world leading developer and marketer of TENS and NMES (neuro-muscle electro-stimulation) devices. He was Co-founder & Vice Chairman of United Shipping & Technology (the largest same day shipping company in North America/NASDAQ). Prior to that he held various positions including: Senior Vice President of Marketing, Gateway Learning; Senior Vice President of Marketing, NordicTrack Company; and various positions at Procter & Gamble in Cincinnati. Mr.Masko has a BA from Northwestern University, and he has an MBA in Marketing & Finance from Northwestern University’s J. L. Kellogg Graduate School of Management.
Thu-Ha Duncan, (Engineering & Technology)
With over 25 years of experience, Ms. Duncan has a tremendous track record in developing medical devices using electric stimulation to affect physiologically remediative medical treatments for neurologic and muscle therapy indications.
Ms. Duncan also has significant experience in developing innovative products that have met and cleared the FDA requirements as well as international requirements. As such, she will be a valuable contributor to the company's product development and regulatory clearance process. Ms. Duncan was formerly the Head of Engineering for Chattanooga Group, Empi, Iomed and DJO Medical, whose market dominance was in the field of electrical stimulation and therapy.
Meredith Mundy, (Clinical Research)
Meredith Mundy is the Founder of Paradigm Research LLC, and manages i-Lumen's clinical research program. She has over 20 years of operational management experience in small to large businesses, and has focused on clinical operations for early stage medical device companies during the last 10 years. These medical devices have included neurostimulation and modulation, ENT applications, systems, software, and implantable devices. Ms. Mundy was most recently with Stryker Corporation, as part of the acquisition of Arrinex, Inc., along with the previous acquisition of Spirox, Inc., where she were she both designed and managed clinical study programs for submissions and post-market surveillance. Meredith brings her highly knowledgeable clinical experience as well as a track record consistent success, to the company.